Recent Quotes (30 days)

You have no recent quotes
chg | %

aTyr Pharma Inc  

(Public, NASDAQ:LIFE)   Watch this stock  
Find more results for LIFE
3.30
-0.03 (-0.90%)
After Hours: 3.30 0.00 (0.00%)
May 25, 4:52PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.16 - 3.39
52 week 2.81 - 28.29
Open 3.35
Vol / Avg. 255,679.00/360,225.00
Mkt cap 80.84M
P/E     -
Div/yield     -
EPS -2.32
Shares 23.69M
Beta     -
Inst. own 91%
Aug 10, 2016
Q2 2016 aTyr Pharma Inc Earnings Release (Estimated) Add to calendar
May 11, 2016
Q1 2016 aTyr Pharma Inc Earnings Release
May 4, 2016
aTyr Pharma Inc at Deutsche Bank Health Care Conference
Apr 13, 2016
aTyr Pharma Inc at Needham Healthcare Conference
Mar 30, 2016
Q4 2015 aTyr Pharma Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -52.72% -63.83%
Return on average equity -59.89% -399.23%
Employees 55 -
CDP Score - -

Address

3545 John Hopkins Ct Ste 250
SAN DIEGO, CA 92121-1115
United States - Map
+1-858-7318389 (Phone)
+1-858-7318394 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

aTyr Pharma, Inc. is a biotherapeutics company. The Company focuses on the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a discovered set of physiological modulators. It focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company's lead candidate, Resolaris, is an intravenous protein therapeutic for the treatment of myopathies with an immune component. Resolaris is in a Phase Ib/II clinical trial in adult patients with FSHD; a Phase Ib/II trial in adult patients with LGMD 2B or FSHD, and a Phase Ib/II trial in patients with early onset FSHD. As of September 30, 2015, the Company had not generated any revenues.

Officers and directors

John D. Mendlein Ph.D. Chief Executive Officer and Executive Chairman, Board of Directors
Age: 56
Bio & Compensation  - Reuters
John T. Blake Principal Financial Officer, Chief Accounting Officer
Age: 39
Bio & Compensation  - Reuters
Melissa A Ashlock Vice President - External Scientific Alliances and Human Genetics
Age: 57
Bio & Compensation  - Reuters
Kelly Blackburn Vice President - Clinical Affairs
Age: 51
Bio & Compensation  - Reuters
Holly D Chrzanowski Vice President - Enterprise Talent and Organization
Age: 49
Bio & Compensation  - Reuters
Andrew Cubitt Vice President - Product Protection
Age: 52
Bio & Compensation  - Reuters
John C McKew Vice President - Research
Age: 51
Bio & Compensation  - Reuters
Fred Ramsdell Vice President - Immunology
Age: 54
Bio & Compensation  - Reuters
Sanuj K Ravindran M.D. Chief Business Officer
Bio & Compensation  - Reuters
Sanjay Shukla M.D. Chief Medical Officer
Bio & Compensation  - Reuters